AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400166-T1: [Translated] FEEDING DEVICE FOR ELECTRICAL COMPONENTS AND ASSOCIATED CONTROL METHOD

The arrangement has an extractor unit for a cover foil of a component belt. A stretching unit stretches the removed foil, where the stretching unit is movably supported relative to a housing. A sensor (26) is provided for acquiring the position of a clamping unit/clamping piece. A control unit (12) is connected with the sensor and is formed to detect an error condition based on the acquired position of the clamping unit. Independent claims are also included for the following: (1) a control method for an electrical component feeding arrangement (2) a control method for a supply system.
AFCARS Report #26

This report provides preliminary estimates of Adoption and Foster Care Analysis and Reporting System (AFCARS) data for FY 2018. As states are permitted to resubmit AFCARS data, the estimates may change over time. This report reflects all AFCARS data received as of August 22, 2019 related to AFCARS reporting periods through September 30, 2018.

Metadata-only record linking to the original dataset. Open original dataset below.
Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion

Background
          GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with plasminogen activator (t-PA) in an experimental model of ischemia reperfusion (I/R) in hamster cheek pouch microcirculation visualized by fluorescence microscopy. Hamsters were treated with saline, or abiciximab or eptifibatide or these drugs combined with t-PA infused intravenously 10 minutes before ischemia and through reperfusion. We measured the microvessel diameter changes, the arteriolar red blood cell (RBC) velocity, the increase in permeability, the perfused capillary length (PCL), and the platelet and leukocyte adhesion on microvessels.
        
        
          Results
          I/R elicited large increases in the platelet and leukocyte adhesion and a decrease in microvascular perfusion. These responses were significantly attenuated by abiciximab or eptifibatide (PCL:70 and 65% at 5–10 mins of reperfusion and 85 and 87% at 30 mins of reperfusion, respectively, p < 0.001) while t-PA combined with abiciximab or eptifibatide, was more effective and microvascular perfusion recovered immediately after postischemic reperfusion.
        
        
          Conclusions
          Platelets are crucial in I/R injury, as shown by the treatment with abicixmab or eptifibatide, which decreased platelet aggregation in microvessels, and also decreased leukocyte adhesion in venules. Arterial vasoconstriction, decreased arterial RBC velocity and alterations in the endothelial barrier with increased permeability delayed the complete restoration of blood flow, while t-PA combined with inhibition of platelet aggregation speeded up the capillary perfusion after reperfusion.
Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis

Hypothalamic–pituitary–adrenal underactivity has been reported in rheumatoid arthritis (RA). This phenomenon has implications with regard to the pathogenesis and treatment of the disease. The present study was designed to evaluate the secretion of the adrenal androgen dehydroepiandrosterone sulfate (DHEAS) and its relation to clinical variables in RA, spondyloarthropathy (Spa), and undifferentiated inflammatory arthritis (UIA). Eighty-seven patients (38 with RA, 29 with Spa, and 20 with UIA) were studied, of whom 54 were women. Only 12 patients (14%) had taken glucocorticoids previously. Age-matched, healthy women (134) and men (149) served as controls. Fasting blood samples were taken for determination of the erythrocyte sedimentation rate (ESR), serum DHEAS and insulin, and plasma glucose. Insulin resistance was estimated by the homeostasis-model assessment (HOMAIR). DHEAS concentrations were significantly decreased in both women and men with inflammatory arthritis (IA) (P < 0.001). In 24 patients (28%), DHEAS levels were below the lower extreme ranges found for controls. Multiple intergroup comparisons revealed similarly decreased concentrations in each disease subset in both women and men. After the ESR, previous glucocorticoid usage, current treatment with nonsteroidal anti-inflammatory drugs, duration of disease and HOMAIR were controlled for, the differences in DHEAS levels between patients and controls were markedly attenuated in women (P = 0.050) and were no longer present in men (P = 0.133). We concluded that low DHEAS concentrations are commonly encountered in IA and, in women, this may not be fully explainable by disease-related parameters. The role of hypoadrenalism in the pathophysiology of IA deserves further elucidation. DHEA replacement may be indicated in many patients with IA, even in those not taking glucocorticoids.
The use of cephalad cannulae to monitor jugular venous oxygen content during extracorporeal membrane oxygenation

Background:
          When used during extracorporeal membrane oxygenation (ECMO), jugular venous bulb catheters, known as cephalad cannulae, increase venous drainage, augment circuit flow and decompress cerebral venous pressure. Optimized cerebral oxygen delivery during ECMO may contribute to a reduction in neurological morbidity. This study describes the use of cephalad cannulae and identifies rudimentary data for jugular venous oxygen saturation (JVO2) and arterial to jugular venous oxygen saturation difference (AVDO2) in this patient population.
        
        
          Results:
          Patients on venoarterial (VA) ECMO displayed higher JVO2 (P < 0.01) and lower AVDO2 (P = 0.01) than patients on venovenous (VV) ECMO (P < 0.01). During VV ECMO, JVO2 was higher and AVDO2 lower when systemic pH was < 7.35 rather than > 7.4 (P = 0.01). During VA ECMO, similar differences in AVDO2 but not in JVO2 were observed at different pH levels (P = 0.01).
        
        
          Conclusions:
          Jugular venous saturation and AVDO2 were influenced by systemic pH, ECMO type and patient age. These data provide the foundation for normative values of JVO2 and AVDO2 in neonates and children treated with ECMO.
A Field-Portable Colorimetric Method for the Measurement of Peracetic Acid Vapors: A Comparison of Glass and Plastic Impingers

A method for measuring PAA vapors in air using impinger sampling and field-portable colorimetric analysis is presented. The capture efficiency of aqueous media in glass and plastic impingers was evaluated when used for PAA vapor sampling. Measurement of PAA was done using a N,N-diethyl-p-phenylenediamine (DPD) colorimetric method with a field portable spectrometer. The linearity of the DPD method was determined for PAA both in-solution and captured from vapor phase using glass or plastic impingers. The Limit of Detection (LOD) for the glass and plastic impinger (0.24 mg/m3 (0.077 mg/L) and 0.28 mg/m3 (0.091 mg/L)), respectively, and Limit of Quantitation (LOQ) (0.79 mg/m3 (0.25 mg/L) and 0.92 mg/m3 (0.30 mg/L) for the glass and plastic impingers, respectively, are below the threshold limit value (TLV) short term exposure limit (STEL) of 1.24 mg/m3 (0.4 ppm) over a 15 minute period. This impinger method allows for a low cost, easy to use, and rapid in-field measurement for occupational exposure to PAA.
Compound 527549: 1,3-Cyclohexadiene, 1-iodo

Chemical compound data from PubChem database. IUPAC Name: 1-iodocyclohexa-1,3-diene. Molecular Formula: C6H7I. Molecular Weight: 206.02. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528807: [3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] hexanoate

Chemical compound data from PubChem database. IUPAC Name: [3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] hexanoate. Molecular Formula: C26H40O2. Molecular Weight: 384.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525905: N,N-Dimethyl-N'-hexyl-pivalamidine

Chemical compound data from PubChem database. IUPAC Name: N'-hexyl-N,N,2,2-tetramethylpropanimidamide. Molecular Formula: C13H28N2. Molecular Weight: 212.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD iMAP: Maryland Long Term Care Assisted Living - Acute General Special Hospitals

This is a MD iMAP hosted service layer. Find more information at http://imap.maryland.gov. OP&R organizes and prepares for public health and medical emergencies through statewide partnerships with public -  private and government agencies to coordinate an effective emergency response for the health and safety of all residents of Maryland. Last Updated:  10/06/2014 Feature Service Layer Link: http://geodata.md.gov/imap/rest/services/Health/MD_LongTermCareAssistedLiving/FeatureServer/7 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively "the Data") is provided "as is" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Boston: Drug-Related Emergency Department Visits, 2004-2011 - Suicide Attempts

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts in the Boston metropolitan area, covering 2004-2011.  Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.
Patent AT-E40105-T1: [Translated] PRODUCTION OF ACETIC ESTERS FROM ALCOHOLS USING RHODIUM COMPLEX CATALYSTS.

A process for the production of acetate esters by the catalytic reaction of an alcohol of the formula ROH and carbon monoxide in contact with a homogeneous catalyst system of rhodium metal atom, a phosphorus containing ligand in which there is present at least one oxo (=O) oxygen atom attached to a phosphorus atom or a carbon atom to form a Z group and the  @ or @   group in said Z group is located at least one carbon atom removed and preferably from 2-4 carbon atoms removed from the phosphorus atom of the molecules represented by the formulas <CHEM>  or <CHEM> and a halogen promoter, under mild reaction conditions, wherein R min is aryl, alkaryl, aralkyl or alkyl, and wherein 1 or more of said R min  groups can be substituted with a Z group but not more than 3 of said R min  groups in the molecule are so substituted: a is an integer from 0-4; b is an integer from 0-3; and Z is P(O)R min R min ; - C(O)OR sec  or C(O)R sec , wherein R sec  is R min  or -H; and wherein ROH is methanol or a mixture of methanol and at least one higher alcohol.
Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease

Background
          Some alterations of the lipoprotein profile have been associated with cerebrovascular disease. Recently, it has been suggested that cerebrovascular disease might play a role in the pathogenesis of both vascular dementia (VD) and Alzheimer's disease (AD). Nevertheless, the possible association of dyslipidemias with VD or AD is still a controversial issue.
        
        
          Methods
          We investigated the lipoprotein profile in 100 older patients with vascular dementia (VD; n°: 60) or Late Onset Alzheimer's Disease (LOAD; n°: 40). The patients were compared with 54 community dwelling non-demented older controls.
        
        
          Results
          After adjustment for functional status, blood sedimentation rate, and serum albumin levels, no differences in lipoprotein profile emerged between the three groups, with the exception of HDL-C that was lower in VD compared with controls. Low HDL-C (< 45 mg/dL) was associated with VD (O.R.: 6.52, C.I. 95%: 1.42–30.70 vs controls, and 4.31, C.I. 95%: 0.93–19.82 vs LOAD), after multivariate adjustment. No differences in plasma lipid levels emerged between the three groups after stratification for apo E4 genotype.
        
        
          Conclusions
          In this cross-sectional study low HDL-C levels are associated with VD, but not with LOAD, in a sample of older subjects.
COVID-19 State Profile Report - South Carolina

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Patent AT-E401405-T1: [Translated] NEW COCOA ALBUMINE AND ITS USE IN PRODUCING COCOA AND CHOCOLATE FLAVOR

Chemical patent from PubChem database. Patent Number: AT-E401405-T1. Title: Chemical Synthesis Method. Filing Date: 2008-05-23. Inventors: Patel, Amit, Jones, Michael. Abstract: A novel method for chemical synthesis is provided, utilizing specific catalysts and reaction conditions to achieve selective transformations with high... IPC Classifications: C12N, C12P, A61K. This patent covers 23 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Combinatorial diversity of fission yeast SCF ubiquitin ligases by homo- and heterooligomeric assemblies of the F-box proteins Pop1p and Pop2p

Background
          SCF ubiquitin ligases share the core subunits cullin 1, SKP1, and HRT1/RBX1/ROC1, which associate with different F-box proteins. F-box proteins bind substrates following their phosphorylation upon stimulation of various signaling pathways. Ubiquitin-mediated destruction of the fission yeast cyclin-dependent kinase inhibitor Rum1p depends on two heterooligomerizing F-box proteins, Pop1p and Pop2p. Both proteins interact with the cullin Pcu1p when overexpressed, but it is unknown whether this reflects their co-assembly into bona fide SCF complexes.
        
        
          Results
          We have identified Psh1p and Pip1p, the fission yeast homologues of human SKP1 and HRT1/RBX1/ROC1, and show that both associate with Pop1p, Pop2p, and Pcu1p into a ~500 kDa SCFPop1p-Pop2p complex, which supports polyubiquitylation of Rum1p. Only the F-box of Pop1p is required for SCFPop1p-Pop2p function, while Pop2p seems to be attracted into the complex through binding to Pop1p. Since all SCFPop1p-Pop2p subunits, except for Pop1p, which is exclusively nuclear, localize to both the nucleus and the cytoplasm, the F-box of Pop2p may be critical for the assembly of cytoplasmic SCFPop2p complexes. In support of this notion, we demonstrate individual SCFPop1p and SCFPop2p complexes bearing ubiquitin ligase activity.
        
        
          Conclusion
          Our data suggest that distinct homo- and heterooligomeric assemblies of Pop1p and Pop2p generate combinatorial diversity of SCFPop function in fission yeast. Whereas a heterooligomeric SCFPop1p-Pop2p complex mediates polyubiquitylation of Rum1p, homooligomeric SCFPop1p and SCFPop2p complexes may target unknown nuclear and cytoplasmic substrates.
The cloning, genomic organization and tissue expression profile of the human  DLG5 gene

Background
          Familial atrial fibrillation, an autosomal dominant disease, was previously mapped to chromosome 10q22. One of the genes mapped to the 10q22 region is DLG5, a member of the MAGUKs (Membrane Associated Gyanylate Kinase) family which mediates intracellular signaling. Only a partial cDNA was available for DLG5. To exclude potential disease inducing mutations, it was necessary to obtain a complete cDNA and genomic sequence of the gene.
        
        
          Methods
          The Northern Blot analysis performed using 3' UTR of this gene indicated the transcript size to be about 7.2 KB. Using race technique and library screening the entire cDNA was cloned. This gene was evaluated by sequencing the coding region and splice functions in normal and affected family members with familial atrial fibrillation. Furthermore, haploid cell lines from affected patients were generated and analyzed for deletions that may have been missed by PCR.
        
        
          Results
          We identified two distinct alternately spliced transcripts of this gene. The genomic sequence of the DLG5 gene spanned 79 KB with 32 exons and was shown to have ubiquitous human tissue expression including placenta, heart, skeletal muscle, liver and pancreas.
        
        
          Conclusions
          The entire cDNA of DLG5 was identified, sequenced and its genomic organization determined.
Minneapolis-St. Paul-Bloomington, MN-WI

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Minneapolis-St. Paul-Bloomington, MN-WI metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Minneapolis-St. Paul-Bloomington metro area, Minnesota, and the U.S. overall.
Compound 529401: 4-Acetoxymethyl-2-methoxyphenol

Chemical compound data from PubChem database. IUPAC Name: (4-hydroxy-3-methoxyphenyl)methyl acetate. Molecular Formula: C10H12O4. Molecular Weight: 196.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527343: 14,18,22,26-Tetramethyl-hentriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 15,19,23,27-tetramethyldotriacontanenitrile. Molecular Formula: C36H71N. Molecular Weight: 518.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD COVID-19 - Probable Deaths by Race and Ethnicity Distribution

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of probable COVID-19 deaths among Maryland residents by race and ethnicity: African American; White; Hispanic; Asian; Other; Unknown.

<b>Description</b>
The MD COVID-19 - Probable Deaths by Race and Ethnicity Distribution data layer is a collection of the statewide confirmed and probable COVID-19 related deaths that have been reported each day by the Vital Statistics Administration by categories of race and ethnicity. A death is classified as probable if the person's death certificate notes COVID-19 to be a probable, suspect or presumed cause or condition. Probable deaths are not yet been confirmed by a laboratory test. Some data on deaths may be unavailable due to the time lag between the death, typically reported by a hospital or other facility, and the submission of the complete death certificate. Confirmed deaths are available from the MD COVID-19 - Confirmed Deaths by Race and Ethnicity Distribution data layer.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Hospital Inpatient Discharges (SPARCS De-Identified): Patient Safety Indicators (PSI) Volume Measures by Hospital: Beginning 2009

The datasets contain hospital discharges counts (numerators, denominators, volume counts), observed, expected and risk-adjusted rates with corresponding 95% confidence intervals for Patient Safety Indicators generated using methodology developed by Agency for Healthcare Research and Quality (AHRQ).

The PSIs are a set of indicators providing information on potential in hospital complications and adverse events following surgeries, procedures, and childbirth. The PSIs were developed by AHRQ after a comprehensive literature review, analysis of ICD-9-CM codes, review by a clinician panel, implementation of risk adjustment, and empirical analyses.

All PSI measures were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data beginning 2009.  US Census data files provided by AHRQ were used to derive denominators for county level (area level) PSI measures.

The mortality, volume and utilization measures PSIs are presented by hospital as rates or counts. Area-level measures are presented by county as rates.
Patent AT-E400157-T1: [Translated] A RING NETWORK FOR A BURST SWITCHED NETWORK WITH DISTRIBUTED MANAGEMENT

Transmitting data in a ring network that transmits bursts and data packets. A path setup message (306) is sent to request a data transmission between a source node (302 i ) and a destination node j (302 j ) through intermediate nodes (302 N ) connecting the source node (302 i ) and the destination node j 302 j . Each intermediate node determines that a connection to a next node along the path is available when the connection to the next node, that normally transmits bursts and data packets, transmits data packets. A current data transmission of data packets on the path is stopped when the entire path is determined to be available.